Skip to main content
. 2014 Dec 26;9(12):e116054. doi: 10.1371/journal.pone.0116054

Table 2. Patients characteristics and treatment response by PIK3CA mutation, copy number variation, PTEN, pAkt, and INPP4B expression.

All patients PIK3CA mutation PIK3CA copy number PTEN pAkt INPP4B
WT Mutationa P Normal/loss Gainb P Low High P Low High P Low High P
N 42 36 7 37 6 12 29 10 30 7 32
Mean age 53.0 53.1 52.6 0.974 53.6 49.8 0.352 51.8 53.2 0.456 54.9 52.4 0.650 53.6 53.0 0.927
Mean tumor size (mm)+SD 34+16 34+17 32+12 0.843 34+16 30+19 0.344 29+13 35+18 0.295 32+16 35+17 0.839 50+24 30+13 0.035
Nodal status
negative 21 (49%) 19 (53%) 2 (29%) 18 (49%) 3 (50%) 6 (50%) 14 (48%) 5 (50%) 15 (50%) 3 (43%) 16 (50%)
positive 22 (51%) 17 (47%) 5 (71%) 0.412 18 (51%) 3 (50%) 0.645 6 (50%) 15 (52%) 1.00 5 (50%) 15 (50%) 1.00 4 (57%) 16 (50%) 1.00
Nuclear grade
1–2 24 (57%) 21 (60%) 3 (43%) 22 (59%) 2 (40%) 7 (58%) 15 (54%) 6 (67%) 16 (53%) 1 (14%) 20 (65%)
3 3 (18%) 14 (40%) 4 (57%) 0.438 15 (41%) 3 (60%) 0.636 5 (42%) 13 (46%) 1.00 3 (33%) 14 (47%) 0.704 6 (86%) 11 (35%) 0.031
ER
negative 23 (53%) 20 (56%) 3 (43%) 19 (51%) 4 (67%) 6 (59%) 16 (55%) 8 (80%) 14 (47%) 3 (43%) 18 (56%)
positive 20 (47%) 16 (44%) 4 (57%) 0.687 18 (49%) 2 (33%) 0.669 6 (50%) 13 (45%) 1.00 2 (20%) 16 (53%) 0.069 4 (57%) 14 (44%) 0.682
PR
negative 32 (74%) 29 (81%) 4 (57%) 28 (76%) 5 (83%) 8 (67%) 23 (79%) 10 (100%) 21 (70%) 4 (57%) 25 (78%)
positive 11 (26%) 7 (19%) 3 (43%) 0.325 9 (24%) 1 (17%) 1.00 4 (33%) 6 (21%) 0.441 0 (0%) 9 (30%) 0.081 3 (43%) 7 (22%) 0.344
Mean ki67+SD 44.7+19 43+19 53+25 0.364 45+20 44+22 0.195 50+22 39+20 0.839 42+22 37+19 42+20 41+18 0.473
Tumor subtype
luminal/HER2 19 (44%) 15 (79%) 4 (21%) 20 (54%) 4 (67%) 6 (50%) 17 (59%) 8 (80%) 15 (50%) 3 (43%) 19 (59%)
HER2 24 (56%) 21 (88%) 3 (13%) 0.68 17 (46%) 2 (33%) 0.678 6 (50%) 12 (41%) 0.734 2 (20%) 15 (50%) 0.145 4 (57%) 13 (41%) 0.677
Treatment response
pCR 26 (60%) 24 (67%) 2 (29%) 22 (59%) 4 (67%) 4 (33%) 21 (72%) 7 (70%) 17 (57%) 3 (43%) 21 (66%)
non-pCR 17 (40%) 12 (33%) 5 (71%) 0.093 15 (41%) 2 (33%) 1.00 8 (67%) 8 (28%) 0.034 3 (30%) 13 (43%) 0.711 4 (57%) 11 (34%) 0.396

WT; wild type, ER; estrogen receptor, PR; progesteron receptor, HER2; human epidermal growth factor 2, PTEN; phosphatase and tensin homolog, INPP4B; inositol polyphosphate 4-phosphatase-II,

a

Mutation was defind as positive if the proportion of mutant DNA was more than 10% by digital PCR analysis.

b

copy number gain was defiend if the copy number of PIK3CA was greater than 1.5 compared to RNaseP.